Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
histamine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Apitox, purified honeybee toxin, lyophilized in saline | BIOLOGICAL | intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections |
| histamine | BIOLOGICAL | imitates pain and erythema of honeybee venom |
Histamine is being investigated for the treatment of pain and inflammation associated with osteoarthritis of the knee. It is currently in Phase 3 clinical development as an investigational therapy for this condition.
Histamine is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being studied for its potential to address pain and inflammation in osteoarthritis of the knee.
Histamine is being developed by Apimeds Pharmaceuticals US, Inc., a company listed under the ticker symbol APUS.
Histamine is in Phase 3 clinical development for osteoarthritis of the knee. It is an investigational drug and has not yet been approved by regulatory authorities.
Histamine has one completed Phase 3 trial, NCT01112722, titled 'Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis.' This trial enrolled 363 participants in the United States and was randomized and double-blind.
Histamine is being studied under the trial name Apitox in the clinical trial NCT01112722. The drug is referred to as histamine in development records, and Apitox is the name used in the trial title.